scholarly journals 2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk

2021 ◽  
Vol 22 (4) ◽  
pp. 259-267
Author(s):  
Min Kyong Moon
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Diabetes Management ◽  
Sglt2 Inhibitors ◽  
Atherosclerotic Cardiovascular Disease ◽  
Patients With Heart Failure

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 7th Clinical Practice Guidelines in 2021. Intense multifactorial intervention including adequate control of glycemia, blood pressure, and low density lipoprotein cholesterol level and use of antiplatelet agents has been shown to reduce cardiovascular risk among patients with type 2 diabetes mellitus. In these recent guidelines, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with proven benefits were recommended in patients with heart failure and/or atherosclerotic cardiovascular disease (ASCVD) as mono- or combination therapy. SGLT2 inhibitors such as dapagliflozin, empagliflozin, and ertugliflozin were recommended preferentially in patients with heart failure. In those with ASCVD, treatment including SGLT2 inhibitors such as empagliflozin and dapagliflozin or GLP-1 RAs such as dulaglutide, liraglutide, and semaglutide as a combination therapy was recommended.

scholarly journals The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF

2019 ◽  
Vol 8 (1) ◽  
pp. 47-53
Author(s):  
Sandeep Prabhu ◽  
Wei H Lim ◽  
Richard J Schilling
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Catheter Ablation ◽  
Patient Group ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Evidence Base ◽  
Patients With Heart Failure ◽  
Recent Developments

AF and heart failure are emerging epidemics worldwide. Several recent trials have provided a growing evidence base for the benefits of catheter ablation in this patient group, which are yet to be universally adopted in clinical practice guidelines. This paper provides a summary of recent developments in this field and provides pragmatic advice to the treating physician regarding the appropriate role of catheter ablation in the overall management of patients with comorbid AF and heart failure.

scholarly journals Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials

2021 ◽  
Vol 26 (3S) ◽  
pp. 4558 ◽  
Author(s):  
S. V. Villevalde ◽  
A. E. Soloveva ◽  
N. E. Zvartau ◽  
N. G. Avdonina ◽  
A. N. Yakovlev ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Management ◽  
Clinical Practice ◽  
Cardiovascular Risk ◽  
Medical Care ◽  
Optimal Model ◽  
Cardiovascular Risk Management ◽  
Patients With Heart Failure ◽  
The Russian Federation ◽  
Real Clinical Practice

The extent of the problem of heart failure determines the priority of the intention of developing and implementing an optimal model of medical care for this group of patients. The article describes the key components of the heart failure medical care (continuity, patient routing, educational activities) and provides examples of documents, protocols, checklists that can be used in real clinical practice by specialists in medical organizations in the regions of the Russian Federation.

scholarly journals Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management

2020 ◽  
pp. 24-29
Author(s):  
M Vally
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Paradigm Shift ◽  
Diabetes Management ◽  
Clinical Trial Data ◽  
Sglt2 Inhibitors ◽  
Atherosclerotic Cardiovascular Disease ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 (GLP-1) analogues are an injectable therapy used in the management of type 2 diabetes. These drugs seem to reduce cardiovascular risk factors and clinical trial data seems to suggest that liraglutide and semaglutide reduce cardiovascular risk in patients with type 2 diabetes and concomitant atherosclerotic cardiovascular disease. The search for agents such as these (and SGLT2 inhibitors) that not only manage diabetes but also reduce cardiovascular risk has resulted in a paradigm shift in the way diabetes can be managed.

scholarly journals Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management

2019 ◽  
Vol 30 (4) ◽  
pp. S121-S140
Author(s):  
Karin D. VanBaak ◽  
Laura M. Nally ◽  
Ryan T. Finigan ◽  
Carrie L. Jurkiewicz ◽  
Andre M. Burnier ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Diabetes Management ◽  
Medical Society

scholarly journals Updated Clinical Practice Guidelines on Heart Failure: An International Alignment

Circulation ◽  
2016 ◽  
Vol 134 (13) ◽  
Author(s):  
Elliott M. Antman ◽  
Jeroen Bax ◽  
Richard A. Chazal ◽  
Mark A. Creager ◽  
Gerasimos Filippatos ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines
Sign in / Sign up

Export Citation Format

Share Document